Municipal Employees Retirement System of Michigan acquired a new position in shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 236,040 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,192,000.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC raised its stake in Juniper Pharmaceuticals by 2.3% in the second quarter. Acadian Asset Management LLC now owns 41,978 shares of the specialty pharmaceutical company’s stock worth $211,000 after buying an additional 941 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Juniper Pharmaceuticals during the first quarter worth $100,000. KCG Holdings Inc. purchased a new stake in Juniper Pharmaceuticals during the first quarter worth $112,000. Renaissance Technologies LLC raised its stake in Juniper Pharmaceuticals by 21.7% in the first quarter. Renaissance Technologies LLC now owns 309,500 shares of the specialty pharmaceutical company’s stock worth $1,470,000 after buying an additional 55,200 shares in the last quarter. Finally, AWM Investment Company Inc. purchased a new stake in Juniper Pharmaceuticals during the first quarter worth $475,000. Institutional investors and hedge funds own 36.75% of the company’s stock.
Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) opened at 4.65 on Thursday. The stock has a market cap of $50.42 million, a P/E ratio of 8.23 and a beta of 0.28. The stock’s 50 day moving average is $5.01 and its 200-day moving average is $4.74. Juniper Pharmaceuticals, Inc. has a one year low of $3.65 and a one year high of $7.15.
Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. The firm had revenue of $13.96 million for the quarter, compared to the consensus estimate of $11.84 million. On average, equities analysts forecast that Juniper Pharmaceuticals, Inc. will post ($0.51) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Municipal Employees Retirement System of Michigan Acquires Shares of 236,040 Juniper Pharmaceuticals, Inc. (JNP)” was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2797017/municipal-employees-retirement-system-of-michigan-acquires-shares-of-236040-juniper-pharmaceuticals-inc-jnp.html.
A number of analysts have weighed in on the stock. BMO Capital Markets upgraded shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $31.00 to $34.00 in a research note on Friday, July 14th. HC Wainwright restated a “hold” rating on shares of Juniper Pharmaceuticals in a research note on Monday, May 15th. Roth Capital set a $12.00 price objective on shares of Juniper Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, May 6th. ValuEngine lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, TheStreet upgraded shares of Juniper Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Wednesday, April 12th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $17.58.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Want to see what other hedge funds are holding JNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juniper Pharmaceuticals, Inc. (NASDAQ:JNP).
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.